Soft tissue sarcomas are cancers that develop in your body’s soft tissues like muscle, fat, tendons, or cartilage. Your legs are the most common place they develop. The American Cancer Society ...

Chronologic changes in the clinicopathologic findings and survival of gastric cancer patients. The records of all patients with AJCC stage IIIB extremity STS treated with preoperative chemotherapy ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the extremity, a randomized trial showed. In patients with mostly undifferentiated ...

Although relatively rare, soft tissue sarcoma after breast cancer treatment was linked most strongly to treatment with radiation, according to data from two large U.S. cohorts of breast cancer ...

The treatment for childhood soft tissue sarcoma depends on the specific type and extent of the cancer. It often involves surgery to remove the cancer and potentially involves chemotherapy or radiation ...

The probability of overall survival after 1, 5, and 10 years was predicted by a nomogram model, which found that worse Surveillance, Epidemiology, and End Results (SEER) stage was associated with ...

Soft tissue sarcomas rarely metastasize to the heart, with cardiac involvement seen in less than 0.03% of cases. Metastatic heart disease presents diagnostic challenges due to nonspecific symptoms, ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results ...